PML and MYC

  • Number of citations of the paper that reports this interaction (PMID 15735755)
  • 12
  • Data Source:
  • BioGRID (affinity chromatography technology, pull down)
  • HPRD (in vivo, in vitro)

PML

MYC

Gene Name promyelocytic leukemia v-myc avian myelocytomatosis viral oncogene homolog
Image
Gene Ontology Annotations Cellular Component
Molecular Function
Biological Process
Pathways
Drugs
Diseases
GWAS
Protein-Protein Interactions 101 interactors: ADH1B ANKRD2 ARID3A ARNT ATF2 ATXN1 AURKA AXIN1 BANP BCL2 BCL6 CASP8AP2 CCNT1 CDK1 CDK2 CDK6 CHFR CREBBP CSNK2A1 DAXX EGFR EIF4E ELF4 EP300 FOS GATA2 HDAC1 HDAC2 HDAC3 HHEX HIPK2 HTT KAT5 KAT6A MAPK11 MAPK14 MDM2 MED7 MXD1 MYB MYC NCOA2 NCOR1 NCOR2 NFKB1 NR3C1 NR4A1 PAWR PAXIP1 PCBD2 PIAS1 PIAS2 PIN1 PLAGL1 PLSCR1 POLR2E PPARG PSMA3 RARA RB1 RBX1 RELA RNF111 RNF125 RNF4 RPL11 RXRA SENP2 SH3GL1 SIAH2 SIN3A SIRT1 SKI SMAD3 SP1 SP100 SRF STAT3 SUMO1 SUMO2 SUMO3 SUV39H1 SYNE2 TDG TERF2IP TGFBR1 TGFBR2 TGIF1 THRA TOPBP1 TP53 TP63 TP73 TRIM24 TRIM27 TRIM69 UBE2I UBE2U UBE3A ZBTB16 ZFYVE9 126 interactors: ACTL6A ATAD2 AXIN1 BCL2 BIN1 BRCA1 BRD3 BTRC CCNH CCNT1 CDC6 CDCA7L CDK1 CDK4 CDK6 CDK8 CDKN2A CEBPA CEBPB CEP57 CREB1 CREBBP CSNK2A1 CSNK2A2 DNMT3A EFNB1 ELF3 EP300 EP400 FBXO8 FBXW7 FBXW8 GCN1L1 GPX2 GSK3A GSK3B GTF2B GTF2F1 GTF2I HNRNPD HSP90AA1 HUWE1 ING4 KAT2A KAT2B KAT5 KDM1A KIAA1524 KIDINS220 KPNA2 LDOC1 MAP2K1 MAPK1 MAPK3 MAPK7 MAPK8 MAX MED1 MED12 MED14 MED16 MEN1 MINA MLH1 MOK MXD1 MXI1 MYCBP MYCBP2 NEK11 NFYB NFYC NMI NOTCH3 NUCB1 PAK2 PARP10 PFDN5 PLAU PML POLR2A PRDX1 PSMC3 RAF1 RB1 RBL1 RELA RUVBL1 SAP130 SF3B1 SKP1 SKP2 SMAD2 SMAD3 SMARCA2 SMARCA4 SMARCB1 SMARCC1 SNIP1 SNRNP70 SP1 SPAG9 SUPT3H TADA2A TAF1B TAF5 TAF9 TBP TFAP2A TFAP2B TIAM1 TONSL TP73 TRIM6 TRRAP TUBA1A TUBA1B TUBA3C TUBA4A TUBA8 UBB USP37 YEATS4 YY1 ZBTB17 ZNF281
Entrez ID 5371 4609
HPRD ID 00023 01818
Ensembl ID ENSG00000140464 ENSG00000136997
Uniprot IDs P29590 P01106
PDB IDs 1BOR 1A93 1EE4 1MV0 1NKP 2A93 2OR9
Enriched GO Terms of Interacting Partners?
Tagcloud ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
augment  augments  bait  cbp  coactivator  coil  coiled  enhances  except  hybrid  ifngamma  instead  interactor  interacts  interestingly  intrinsic  lacks  nmi  potentiate  recruitment  reveal  screen  stat  stat1  stat2  stat5  stat5b  stats  yeast 
Tagcloud (Difference) ?
anthracycline  apl  approaches  appropriately  arsenic  corepressors  curable  cure  deacetylase  effectiveness  explain  explains  incorporation  minority  oncogenes  pathogenetic  plzf  progranulocytic  promoters  ra  rar  recruit  refinement  relapsed  repression  safe  timed  trioxide  vast 
augment  augments  bait  cbp  coactivator  coil  coiled  enhances  except  hybrid  ifngamma  instead  interactor  interacts  interestingly  intrinsic  lacks  nmi  potentiate  recruitment  reveal  screen  stat  stat1  stat2  stat5  stat5b  stats  yeast 
Tagcloud (Intersection) ?